{
    "title": "112_s1356",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Affordable Medicines Utilization Act \nof 2011''.\n\nSEC. 2. SAVINGS REBATE FOR STATES THAT INCREASE GENERIC DRUG \n              UTILIZATION UNDER MEDICAID.\n\n    (a) In General.--Section 1903 of the Social Security Act (42 U.S.C. \n1396b) is amended by inserting after subsection (g), the following:\n    ``(h)(1) With respect to each of fiscal years 2012, 2013, and 2014, \nif the generic substitution rate determined for the State under section \n1927(l)(2) for the most recent preceding fiscal year for which data is \navailable is greater than the State's generic substitution rate (as so \ndetermined) for the most recent second preceding fiscal year for which \ndata is available, the amount determined under subsection (a) for the \nState for each quarter of the fiscal year shall be increased by the \namount equal to 50 percent of the generic drug utilization savings \namount determined for the State and the quarter under paragraph (2).\n    ``(2) The generic drug utilization savings amount determined under \nthis paragraph with respect to a State and a quarter is the product \nof--\n            ``(A) the difference between the--\n                    ``(i) total amount expended by the State for the \n                corresponding quarter of the preceding fiscal year for \n                providing medical assistance for multiple source drugs \n                (as defined in section 1927(k)(7)(A)(i)), as determined \n                after the application of section 1927(b)(1)(B); and\n                    ``(ii) total amount expended by the State for the \n                quarter involved for providing medical assistance for \n                such drugs (as so determined); and\n            ``(B) the State percentage determined for the State under \n        section 1905(b).''.\n    (b) Annual Determination of State Generic Substitution Rates and \nPerformance Rankings.--Section 1927 of the Social Security Act (42 \nU.S.C. 1396r-8) is amended by adding at the end the following:\n    ``(l) Annual Determination of State Generic Substitution Rates and \nPerformance Rankings.--\n            ``(1) In general.--Not later than January 1, 2012, and \n        annually thereafter, the Secretary shall determine the generic \n        substitution rate (as defined in paragraph (2)) for each State \n        for the most recent preceding fiscal year and the most recent \n        second preceding fiscal year for which data are available. The \n        Secretary annually shall publish on the Internet Web site of \n        the Centers for Medicare & Medicaid Services the generic \n        substitution rates determined for each State for such preceding \n        fiscal years and the percentage increase or decrease in such \n        rates when compared with each other with respect to a State. On \n        the basis of such comparison, the Secretary shall list the \n        States in order of the States with the greatest increase in the \n        generic substitution rate.\n            ``(2) Generic substitution rate.--In paragraph (1), the \n        term `generic substitution rate' means, with respect to a \n        State, the share of all drug units for which payment is made to \n        the State under this title for the 20 most widely prescribed \n        multiple source drugs under the State program under this title \n        that have a specific National Drug Code and meet the \n        requirements of subsection (k)(7)(A)(i).''.\n    (c) Evaluation and Report.--\n            (1) In general.--Not later than December 31, 2014, the \n        Secretary of Health and Human Services shall evaluate and \n        report to Congress on the effectiveness of the generic drug \n        utilization savings payments authorized under section 1903(h) \n        of the Social Security Act (42 U.S.C. 1396b(h)) (as added by \n        subsection (a)) in encouraging States to increase their \n        Medicaid generic substitution rate. The evaluation shall \n        include (but is not limited to) the following:\n                    (A) An analysis of the amounts each State Medicaid \n                program saves through increased generic drug \n                substitution.\n                    (B) An analysis of any indirect savings to State \n                Medicaid programs through increased medication \n                adherence due to increased accessibility and \n                affordability of prescriptions.\n                    (C) An analysis of future estimated savings to \n                State Medicaid programs and the Federal Government \n                after termination of the generic drug utilization \n                savings payments authorized under such section.\n            (2) Medicaid generic substitution rate.--In paragraph (1), \n        the term ``Medicaid generic substitution rate'' has the meaning \n        given the term ``generic substitution rate'' with respect to a \n        State under 1927(l)(2) of the Social Security Act (42 U.S.C. \n        1396r-8(l)(2)) (as added by subsection (b))."
}